Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCC

June 15th 2023

Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.

Frontline Pembrolizumab Plus Lenvatinib Has Antitumor Activity in Non–clear Cell RCC

June 14th 2023

The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell renal cell carcinoma, according to findings from the phase 2 KEYNOTE-B61 trial.

Dr Choueiri on the Results of the CONTACT-03 Trial in Metastatic RCC

June 12th 2023

Toni Choueiri, MD, discusses the results of the phase 3 CONTACT-03 trial (NCT04338269) of atezolizumab and cabozantinib in patients with metastatic renal cell carcinoma.

Resection Should be Considered for Residual Non-Retroperitoneal Disease in Post-Chemo NSGCTs

June 8th 2023

Although patients with metastatic nonseminomatous germ-cell tumors who had teratoma in the primary tumor were found to have a higher rate of teratoma in residual non-retroperitoneal disease following chemotherapy, those without teratoma in the primary tumor could have teratoma or active testicular germ-cell tumors in residual disease post-chemotherapy and should be considered for resection.

Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC

June 7th 2023

Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC

June 5th 2023

The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.

Multidisciplinary Strategies in RCC Management: Future Directions in Care

June 5th 2023

Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

June 5th 2023

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Cabozantinib Plus Nivolumab and Ipilimumab Elicits Meaningful Activity in RCCvh

June 3rd 2023

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI

June 3rd 2023

Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.

Dr Srour on Next Steps Planned for the Investigation of ALLO-316 in Advanced Clear Cell RCC

June 2nd 2023

Samer A. Srour, MB ChB, MS, discusses planned next steps and future avenues of investigation for the novel CD70-targeted agent ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer

June 1st 2023

Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Combination IO TKI Therapy in Patients With Metastatic Renal Cell Carcinoma

May 29th 2023

Focused discussion on combination IO-TKI therapy and its role as first-line therapy in patients diagnosed with metastatic renal cell carcinoma.

Scenario 2: A 59-Year-Old Man With Favorable Risk Metastatic RCC

May 29th 2023

Moving on to the second patient scenario of renal cell carcinoma, panelists reflect on the treatment pathway for favorable risk metastatic disease.

Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC

May 24th 2023

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC

May 23rd 2023

Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.

Sintilimab/Axitinib Combo Shrinks FH-Deficient RCC Tumors

May 23rd 2023

Xingming Zhang, MD, discusses unmet needs in fumarate hydratase–deficient renal cell carcinoma; shares key efficacy, safety, and quality of life findings from a phase 2 trial of sintilimab plus axitinib; and elaborates on the next steps for this research, including an analysis of biomarkers and potential resistance mechanisms.

Dr Srour on the Mechanism of Action of ALLO-316 in Metastatic Clear Cell RCC

May 22nd 2023

Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.